222 related articles for article (PubMed ID: 30843536)
1. Which is the destiny of ulipristal acetate for uterine fibroids? A commentary on the Italian medicines agency (AIFA) pronouncements.
Indraccolo U; Conzadori S; Greco P
Recenti Prog Med; 2019 Feb; 110(2):98-99. PubMed ID: 30843536
[TBL] [Abstract][Full Text] [Related]
2. Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program.
Donnez J; Arriagada P; Marciniak M; Larrey D
Expert Opin Drug Saf; 2018 Dec; 17(12):1225-1232. PubMed ID: 30460871
[TBL] [Abstract][Full Text] [Related]
3. What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate?
Pourcelot AG; Capmas P; Laberge P; Fernandez H
J Gynecol Obstet Hum Reprod; 2020 Apr; 49(4):101688. PubMed ID: 31972353
[TBL] [Abstract][Full Text] [Related]
4. Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya.
Mozzanega B
J Hepatol; 2021 Mar; 74(3):750-751. PubMed ID: 33271158
[No Abstract] [Full Text] [Related]
5. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
6. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
7. Fibroid management in premenopausal women.
Donnez J; Courtoy GE; Dolmans MM
Climacteric; 2019 Feb; 22(1):27-33. PubMed ID: 30601065
[TBL] [Abstract][Full Text] [Related]
8. Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up.
Nicolás I; Martínez-Zamora MÁ; Gracia M; Carrion A; Feixas G; Bernal L; Quintas L; Rius M; Castelo-Branco C; Carmona F
Gynecol Endocrinol; 2021 Sep; 37(9):831-835. PubMed ID: 34044726
[TBL] [Abstract][Full Text] [Related]
9. Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis.
Gatti M; Poluzzi E; De Ponti F; Raschi E
Drug Saf; 2020 Dec; 43(12):1277-1285. PubMed ID: 32748236
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
Ferrero S; Vellone VG; Barra F
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
[TBL] [Abstract][Full Text] [Related]
11. Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
Ekanem E; Talaulikar V
Adv Ther; 2021 Jan; 38(1):137-148. PubMed ID: 33201387
[TBL] [Abstract][Full Text] [Related]
12. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
13. An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids.
Kang S; Brinker A; Jones SC; Dimick-Santos L; Avigan MI
Drug Saf; 2020 Dec; 43(12):1267-1276. PubMed ID: 32647996
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, toxicological and clinical aspects of ulipristal acetate: insights into the mechanisms implicated in the hepatic toxicity.
Dinis-Oliveira RJ
Drug Metab Rev; 2021 Aug; 53(3):375-383. PubMed ID: 33905271
[TBL] [Abstract][Full Text] [Related]
15. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA's review of liver injury risk: Unfortunate timing during the Covid-19 pandemic!
Rozenberg S; Revercez P; Fastrez M; Vandromme J; Bucella D
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():300-302. PubMed ID: 32650189
[TBL] [Abstract][Full Text] [Related]
16. Repeated-intermittent use of ulipristal acetate for the management of uterine fibroids: an Italian pharmacoeconomic evaluation.
Maratea D
Minerva Ginecol; 2016 Feb; 68(1):15-20. PubMed ID: 26990098
[TBL] [Abstract][Full Text] [Related]
17. Liver function, tolerability and satisfaction during treatment with ulipristal acetate in women with fibroids: a single center experience.
Del Forno S; Degli Esposti E; Salucci P; Leonardi D; Iodice R; Arena A; Raimondo D; Paradisi R; Seracchioli R
Gynecol Endocrinol; 2020 May; 36(5):445-447. PubMed ID: 31646908
[TBL] [Abstract][Full Text] [Related]
18. Acute liver failure requiring transplantation: A possible link to ulipristal acetate treatment?
Dinis-Oliveira RJ; Vieira DN
Basic Clin Pharmacol Toxicol; 2021 Sep; 129(3):278-282. PubMed ID: 34187080
[TBL] [Abstract][Full Text] [Related]
19. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
20. Ulipristal acetate versus leuprolide acetate for uterine fibroids.
Donnez J; Tomaszewski J; Vázquez F; Bouchard P; Lemieszczuk B; Baró F; Nouri K; Selvaggi L; Sodowski K; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):421-32. PubMed ID: 22296076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
